Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of chronic migraine~* More than 15 headache days in a 28 day period (headaches that last more than 4 hours and/or require treatment with prescription medication).~Exclusion Criteria:~* Taking opioid-containing products for acute headache treatment more than 8 days during a 28-day period~* Previous treatment with botulinum toxin of any serotype for any reason~* Previous treatment with topiramate~* On a ketogenic diet (high in fat, low in carbohydrates)~* History of acute myopia or increased intraocular pressure~* Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis or any other significant disease that might interfere with neuromuscular function~* Acupuncture, transcutaneous electrical stimulation (TENS), cranial traction, dental splints for headache, or injection of anesthetics/steroids in the 4 weeks prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BOTOX® (Type: ACTIVE_COMPARATOR): 155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks for up to 3 treatments.
- Topiramate (Type: ACTIVE_COMPARATOR): Topiramate starting at a daily oral dose of 25 mg/day titrated up to a maximum dose of 100 mg/day for 36 weeks. Participants who discontinue topiramate are eligible to receive treatment with BOTOX®.

Based on this trial design, predict the completion outcome and termination type (if applicable).